Plain-English translation of NCT06249932 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing empagliflozin (a medication called Jardiance) to see if it can safely help people who have end-stage kidney disease on dialysis and a weakened heart. Most research on this type of medication has been done in people with working kidneys, so doctors want to know if it still works and is safe for people whose kidneys no longer function.
Many people on dialysis also have a weak heart, which increases their risk of serious heart problems and death. This medication has been shown to help people with weak hearts, but it has never been properly studied in patients on dialysis, so doctors don't yet know if it will be effective or safe for them.
You likely qualify if…
You likely don't qualify if…
You will take either the medication or a placebo (a pill with no active ingredient) once per day for 6 months. Neither you nor the researchers will know which one you're taking. During this time, you'll continue your regular dialysis and have follow-up visits to check on your heart health and how you're doing with the medication.
AI-generated summary from trial data · Jul 20, 2026 · Not medical advice
Taiwan